Movement Alert｜Arrowhead Pharmaceuticals Falls 6.35% in Pre-Market Trading, Trading at $66.86

Market Focus

Sep 30

On September 30, Arrowhead Pharmaceuticals fell 6.35% in pre-market trading, trading at $66.86 USD/share, with Turnover of $2,542.03.

Within the Biotechnology sector where Arrowhead Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, Moderna up 0.33%, Amgen up 0.24%, Iovance Biotherapeutics down 1.31%, AbbVie up 0.21%, Natera up 0.73%.

Arrowhead Pharmaceuticals develops medicines based on RNA interference mechanisms, silencing disease-causing genes to treat intractable diseases. The company currently has 18 drug candidates across early-to-late-stage clinical trials and recently secured EU marketing authorization for Redemplo (Plozasiran) to treat Familial Chylomicronaemia Syndrome, with plans to submit a supplemental new drug application to the FDA by year-end using a priority review voucher.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/news/1131126574"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131126574\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131126574?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 16:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131126574","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Arrowhead Pharmaceuticals Falls 6.35% in Pre-Market Trading, Trading at $66.86","media":"Market Focus","content":"<p><p>On September 30, Arrowhead Pharmaceuticals fell 6.35% in pre-market trading, trading at $66.86 USD/share, with Turnover of $2,542.03.</p><p>Within the Biotechnology sector where Arrowhead Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, Moderna up 0.33%, Amgen up 0.24%, Iovance Biotherapeutics down 1.31%, AbbVie up 0.21%, Natera up 0.73%.</p><p>Arrowhead Pharmaceuticals develops medicines based on RNA interference mechanisms, silencing disease-causing genes to treat intractable diseases. The company currently has 18 drug candidates across early-to-late-stage clinical trials and recently secured EU marketing authorization for Redemplo (Plozasiran) to treat Familial Chylomicronaemia Syndrome, with plans to submit a supplemental new drug application to the FDA by year-end using a priority review voucher.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Arrowhead Pharmaceuticals Falls 6.35% in Pre-Market Trading, Trading at $66.86</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Arrowhead Pharmaceuticals Falls 6.35% in Pre-Market Trading, Trading at $66.86\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-30 16:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 30, Arrowhead Pharmaceuticals fell 6.35% in pre-market trading, trading at $66.86 USD/share, with Turnover of $2,542.03.</p><p>Within the Biotechnology sector where Arrowhead Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, Moderna up 0.33%, Amgen up 0.24%, Iovance Biotherapeutics down 1.31%, AbbVie up 0.21%, Natera up 0.73%.</p><p>Arrowhead Pharmaceuticals develops medicines based on RNA interference mechanisms, silencing disease-causing genes to treat intractable diseases. The company currently has 18 drug candidates across early-to-late-stage clinical trials and recently secured EU marketing authorization for Redemplo (Plozasiran) to treat Familial Chylomicronaemia Syndrome, with plans to submit a supplemental new drug application to the FDA by year-end using a priority review voucher.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1131126574","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131126574","pubTimestamp":1790758312,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 30, Arrowhead Pharmaceuticals fell 6.35% in pre-market trading, trading at $66.86 USD/share, with Turnover of $2,542.03.Within the Biotechnology sector where Arrowhead Pharmaceuticals...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"走势警报|Arrowhead Pharmaceuticals 盘前交易中下跌 6.35%，交易价格为 66.86 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"On September 30, Arrowhead Pharmaceuticals fell 6.35% in pre-market trading, trading at $66.86 USD/share, with Turnover of $2,542.03.Within the Biotechnology sector where Arrowhead Pharmaceuticals belongs, the overall sector performance was mixed. Among individual stocks, Moderna up 0.33%, Amgen up 0.24%, Iovance Biotherapeutics down 1.31%, AbbVie up 0.21%, Natera up 0.73%.Arrowhead Pharmaceuticals develops medicines based on RNA interference mechanisms, silencing disease-causing genes to treat intractable diseases. The company currently has 18 drug candidates across early-to-late-stage clinical trials and recently secured EU marketing authorization for Redemplo (Plozasiran) to treat Familial Chylomicronaemia Syndrome, with plans to submit a supplemental new drug application to the FDA by year-end using a priority review voucher.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}